Form 8-K LIGAND PHARMACEUTICALS For: Aug 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Roth Still Positive on Ligand (LGND) Following Q2 Results, ASPIRE Phase 3 Update (AMGN)
August 4, 2014 2:24 PM EDTRoth Capital affirms Ligand Pharma (Nasdaq: LGND) with a Buy rating and $92 price target following Q2 results and update issued earlier Monday.
Analyst Joseph Pantginis commented We believe LGND is in its strongest financial position to date with a growing cash balance, debt fully... More
Ligand Pharmaceuticals, Inc. (LGND) Tops Q2 EPS by 10c; Boosts FY14 Outlook
August 4, 2014 8:40 AM EDTLigand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q2 EPS of $0.24, $0.10 better than the analyst estimate of $0.14. Revenue for the quarter came in at $10.6 million versus the consensus estimate of $9.73 million.
Ligand Pharmaceuticals, Inc. sees Q3 2014 EPS of $0.26-$0.29, versus the consensus of $0.4. Ligand... More
